TY - JOUR
T1 - Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer
AU - Helzlsouer, Kathy J.
AU - Selmin, Ornella
AU - Huang, Han Yao
AU - Strickland, Paul T.
AU - Hoffman, Sandra
AU - Alberg, Anthony J.
AU - Watson, Mary
AU - Comstock, George W.
AU - Bell, Douglas
N1 - Funding Information:
Supported by Public Health Service (PHS) grant CA62988 (National Cancer Institute), by PHS Career Research Award (to G. W. Comstock) HL21670 (National Heart, Lung, and Blood Institute), and by PHS grant ES03819 (National Institute of Environmental Health Sciences), National Institutes of Health, Department of Health and Human Services; and by grant DAMD17-94-J-4265 from the U.S. Department of Defense.
PY - 1998/4/1
Y1 - 1998/4/1
N2 - Background: Glutathione S-transferases (GSTs) are encoded by a superfamily of genes and play a role in the detoxification of potential carcinogens. In a nested case-control study, we investigated associations between genetic variability in specific GST genes (GSTM1, GSTT1, and GSTP1) and susceptibility to breast cancer. Methods: In 1989, a total of 32898 individuals donated blood samples to a research specimen bank established in Washington County, MD. Genotypes of blood specimen DNA were determined for 110 of 115 women with incident cases of breast cancer diagnosed during the period from 1990 through 1995 and up to 113 of 115 control subjects. Associations between specific genotypes and the development of breast cancer were examined by use of logistic regression to calculate odds ratios (ORs) and 95 % confidence intervals (CIs). Results: The GSTM1 homozygous null genotype was associated with an increased risk of developing breast cancer (OR = 2.10; 95 % CI = 1.22-3.64), principally due to an association with postmenopausal breast cancer (OR = 2.50; 95%CI = 1.34-4.65). For GSTP1, the data were suggestive of a trend of increasing risk with higher numbers of codon 105 valine alleles (compared with isoleucine alleles); a 1.97-fold increased risk of breast cancer (95% CI = 0.77-5.02) was associated with valine/valine homozygosity. The risk of breast cancer associated with the GSTT1 homozygous null genotype was 1.50 (95% CI = 0.76-2.95). The risk of breast cancer increased as the number of putative high-risk genotypes increased (P for trend <.001) (OR = 3.77; 95% CI = 1.10-12.88 for a combined genotype of GSTM1 null, GSTT1 null, and either GSTP1 valine heterozygosity or GSTP1 valine homozygosity). Conclusions: Our findings suggest that genetic variability in members of the GST gene family may be associated with an increased susceptibility to breast cancer.
AB - Background: Glutathione S-transferases (GSTs) are encoded by a superfamily of genes and play a role in the detoxification of potential carcinogens. In a nested case-control study, we investigated associations between genetic variability in specific GST genes (GSTM1, GSTT1, and GSTP1) and susceptibility to breast cancer. Methods: In 1989, a total of 32898 individuals donated blood samples to a research specimen bank established in Washington County, MD. Genotypes of blood specimen DNA were determined for 110 of 115 women with incident cases of breast cancer diagnosed during the period from 1990 through 1995 and up to 113 of 115 control subjects. Associations between specific genotypes and the development of breast cancer were examined by use of logistic regression to calculate odds ratios (ORs) and 95 % confidence intervals (CIs). Results: The GSTM1 homozygous null genotype was associated with an increased risk of developing breast cancer (OR = 2.10; 95 % CI = 1.22-3.64), principally due to an association with postmenopausal breast cancer (OR = 2.50; 95%CI = 1.34-4.65). For GSTP1, the data were suggestive of a trend of increasing risk with higher numbers of codon 105 valine alleles (compared with isoleucine alleles); a 1.97-fold increased risk of breast cancer (95% CI = 0.77-5.02) was associated with valine/valine homozygosity. The risk of breast cancer associated with the GSTT1 homozygous null genotype was 1.50 (95% CI = 0.76-2.95). The risk of breast cancer increased as the number of putative high-risk genotypes increased (P for trend <.001) (OR = 3.77; 95% CI = 1.10-12.88 for a combined genotype of GSTM1 null, GSTT1 null, and either GSTP1 valine heterozygosity or GSTP1 valine homozygosity). Conclusions: Our findings suggest that genetic variability in members of the GST gene family may be associated with an increased susceptibility to breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0032054961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032054961&partnerID=8YFLogxK
U2 - 10.1093/jnci/90.7.512
DO - 10.1093/jnci/90.7.512
M3 - Article
C2 - 9539246
AN - SCOPUS:0032054961
SN - 0027-8874
VL - 90
SP - 512
EP - 518
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 7
ER -